Claims
- 1. A compound of structural formula: ##STR24## or pharmaceutically acceptable salt thereof wherein m is 0 or 1;
- R" is H or C.sub.2 -.sub.6 alkanoyl;
- A is ##STR25## or --C.tbd.C-- where R.sup.7 is hydrogen, chloro or fluoro;
- R is C.sub.1 -.sub.3 alkyl, hydroxy, C.sub.2 -.sub.6 alkanoyloxy, or hydroxy - C.sub.1 -.sub.3 alkyl;
- R.sup.1 and R.sup.2 are hydrogen or C.sub.1 - .sub.3 alkyl; and
- R.sup.4 is hydrogen, C.sub.1 -.sub.3 alkyl, phenyl, chloro, fluoro, or carboxyl.
- 2. 2-Methyl-3-hydroxy-4-mercaptomethyl-5-vinylpyridine or pharmaceutically acceptable salt thereof.
- 3. 2-Methyl-3-hydroxy-4-mercaptomethylpyridine-5-acrylic acid or a pharmaceutically acceptable salt thereof.
- 4. 2-Methyl-3-hydroxy-4-mercaptomethyl-5-(1-propenyl)pyridine or a pharmaceutically acceptable salt thereof.
- 5. 2-Methyl-3-hydroxy-4-mercaptomethyl-5-ethynylpyridine or a pharmaceutically acceptable salt thereof.
- 6. 2-Methyl-3-hydroxy-4-mercaptomethyl-5-styrylpyridine or pharmaceutically acceptable salt thereof.
- 7. The compound of claim 1 of structural formula: ##STR26## wherein R", A, and R.sup.4 have the same meaning as set forth in said claim.
- 8. An anti-inflammatory composition in unit dosage form comprising a pharmaceutically acceptable inert carrier and from 5 mg. to 5 gm. of a compound of structural formual: ##STR27## or pharmaceutically acceptable salt thereof wherein m is 0 or 1;
- R" is H or C.sub.2 -.sub.6 alkanoyl;
- A is ##STR28## or --C.tbd.C-- where R.sup.7 is hydrogen, chloro or fluoro;
- R is C.sub.1 -.sub.3 alkyl, hydroxy, C.sub.2 -.sub.6 alkanoyloxy, or hydroxy - C.sub.1 -.sub.3 alkyl;
- R.sup.1 and R.sup.2 are hydrogen or C.sub.1 -.sub.3 alkyl; and
- R.sup.4 is hydrogen, C.sub.1 -.sub.3 alkyl, phenyl, chloro, fluoro, or carboxyl.
- 9. The anti-inflammatory composition of claim 8 wherein the active ingredient is a compound of structural formula: ##STR29## wherein R", A and R.sup.4 have the same meaning as set forth in said claim.
- 10. The anti-inflammatory composition of claim 9 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethy-5-vinylpyridine or pharmaceutically accpetable salt thereof.
- 11. The anti-inflammatory composition of claim 9 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethylpyridine-5-acrylic acid or pharmaceutically acceptable salt thereof.
- 12. The anti-inflammatory composition of claim 9 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethyl-5-(1-propenyl) pyridine or pharmaceutically acceptable salt thereof.
- 13. The anti-inflammatory composition of claim 9 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethyl-5-ethynylpyridine or pharmaceutically acceptable salt thereof.
- 14. The anti-inflammatory composition of claim 9 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethyl-5-styrylpyridine or pharmaceutically accpetable salt thereof.
- 15. A method of treating rheumatoid arthritis which comprises the administration, to a warm-blooded animal or human in need of such treatment, an effective amount of a compound of structural formula: ##STR30## or pharmaceutically acceptable salt thereof wherein m is 0 or 1;
- R" is H or C.sub.2 -.sub.6 alkanoyl;
- A is ##STR31## or -- C.dbd.C-- where R.sup.7 is hydrogen, chloro or fluoro;
- R is C.sub.1 -.sub.3 alkyl, hydroxy, C.sub.2-6 alkanoyloxy, or hydroxy - C.sub.1 -.sub.3 alkyl;
- R.sup.1 and R.sup.2 are hydrogen as C.sub.1 -.sub.3 alkyl; and
- R.sup.4 is hydrogen, C.sub.1 -.sub.3 alkyl, phenyl, chloro, fluoro, or carboxyl.
- 16. The method of claim 15 wherein the compound is of structural formula: ##STR32## wherein R", A, and R.sup.4 have the same meaning as set forth in said claim.
- 17. The method of claim 16 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethyl-5-vinylpyridine or pharmaceutically acceptable salt thereof.
- 18. The method of claim 16 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethylpyridine-5-acrylic acid or pharmaceutically acceptable salt thereof.
- 19. The method of claim 16 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethy-5-(1-propenyl) pyridine or pharmaceutically acceptable salt thereof.
- 20. The method of claim 16 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethyl-5-ethynylpyridine or pharmaceutically acceptable salt thereof.
- 21. The method of claim 16 wherein the compound is 2-methyl-3-hydroxy-4-mercaptomethyl-5-styrylpyridine or pharmaceutically acceptable salt thereof.
Parent Case Info
This is a division of application Ser. No. 578,692, filed, May 19, 1975, now abandoned, which in turn is a continuation-in-part of co-pending application Ser. No. 464,011, filed Apr. 26, 1974, now abandoned, which in turn is a continuation-in-part of application Ser. No. 368,772, filed June 15, 1973, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3971797 |
Shen et al. |
Jul 1976 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
578692 |
May 1975 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
464011 |
Apr 1974 |
|
Parent |
368772 |
Jun 1973 |
|